Martina Ferrante
Overview
Explore the profile of Martina Ferrante including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
135
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ferrante M, Furlan D, Zibellini S, Borriero M, Candido C, Sahnane N, et al.
Diagnostics (Basel)
. 2021 Apr;
11(5).
PMID: 33926007
In IgM monoclonal gammopathies MYD88 is a prognostic and predictive biomarker of therapy response. MYD88 detection is mainly performed by allele-specific quantitative PCR (ASqPCR), however recently, droplet digital PCR (ddPCR)...
12.
Genuardi E, Klous P, Mantoan B, Drandi D, Ferrante M, Cavallo F, et al.
Hematol Oncol
. 2021 Mar;
39(3):293-303.
PMID: 33742718
Minimal residual disease (MRD) monitoring by PCR methods is a strong and standardized predictor of clinical outcome in mantle cell lymphoma (MCL) and follicular lymphoma (FL). However, about 20% of...
13.
Della Starza I, De Novi L, Cavalli M, Novelli N, Soscia R, Genuardi E, et al.
Hematol Oncol
. 2020 Aug;
38(5):698-704.
PMID: 32816326
Minimal residual disease (MRD) assessment is of high clinical relevance in patients with mantle cell lymphoma (MCL). In mature B-cell malignancies, the presence of somatic hypermutations (SHM) in Variable-Diversity-Joining Heavy...
14.
Drandi D, Alcantara M, Benmaad I, Sohlbrandt A, Lhermitte L, Zaccaria G, et al.
Hemasphere
. 2020 Apr;
4(2):e347.
PMID: 32309784
Minimal residual disease (MRD) has been increasingly investigated in mantle cell lymphoma (MCL), including for individual therapeutic stratification and pre-emptive treatment in clinical trials. Although patient/allele specific real-time quantitative polymerase...
15.
Lo Schirico M, Ferrante M, Dogliotti I, Zamo A, Ferrero B, Bertuzzo D, et al.
Hemasphere
. 2020 Feb;
4(1):e324.
PMID: 32072140
No abstract available.
16.
Grimaldi D, Genuardi E, Ferrante M, Ferrero S, Ladetto M
Curr Treat Options Oncol
. 2018 Nov;
19(12):71.
PMID: 30402764
Indolent non-Hodgkin lymphomas (iNHL) are a heterogeneous group of pathologies characterized by a prolonged natural history and good response to treatment. They also have a tendency to relapse, in some...
17.
Drandi D, Genuardi E, Dogliotti I, Ferrante M, Jimenez C, Guerrini F, et al.
Haematologica
. 2018 Mar;
103(6):1029-1037.
PMID: 29567768
We here describe a novel method for mutation detection and minimal residual disease monitoring in Waldenström macroglobulinemia, by droplet digital polymerase chain reaction, in bone marrow and peripheral blood cells,...
18.
Simiele M, Ariaudo A, De Nicolo A, Favata F, Ferrante M, Carcieri C, et al.
J Pharm Biomed Anal
. 2017 Feb;
138:223-230.
PMID: 28219799
Rilpivirine (RPV), dolutegravir (DTG) and elvitegravir (EVG) are the latest antiretroviral drugs approved for treatment of HIV infection. Currently, poor information is currently available concerning their pharmacokinetic and pharmacodynamic properties,...